Radiopharm Theranostics Limited

—As of Sun 8 Nov 2026, 12:00 UTC

ASX:RADHealthcare

Country Australia

PE (Fwd) •••

TSR 5Y CAGR (58.93%)

Div yield —

ROE (174.71%)

Biotechnology

Beta (5Y) 0.87

PE TTM —

TSR TTM (83.33%)

Mkt cap A$17.35M

ROIC (101.53%)

SE Grade™

Value

Quality

Moat

Consensus

Reference

$0.0044

10.61%

(82.59%)

Hold 1|7|1|11|12

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

2.339

Revenue$M

1.441

1.482

1.552

1.647

1.750

1.859

1.925

1.961

2.014

2.113

2.400

3.84%

4.27%

49

2.42

Revenue growth%

8.40

6.89

9.33

7.75

6.65

3.81

2.38

3.48

5.95

8.01

4.96

3.81

6.77

50

10.29

Gross margin%

0.40

0.40

2.61

2.56

5.42

2.77

1.34

0.40

0.40

0.84

16.90

0.84

1.09

52

20.46

Operating margin%

29.41

27.63

25.40

23.46

21.06

19.40

21.26

23.12

23.04

22.99

4.75

22.99

23.08

56

3.11

Net margin%

11.95

10.31

7.93

5.47

7.42

5.17

7.18

6.51

9.32

11.23

13.15

7.18

7.68

34

25.03

P/E ratio (avg)x

7.973

7.837

8.303

8.731

7.438

7.368

7.755

7.947

8.252

7.064

18.71

7.755

7.892

65

11.27

EV/EBITx

13.43

12.44

11.88

12.43

14.01

14.31

14.08

13.95

13.02

12.75

37.94

13.95

13.23

40

11.18

FCF yield (avg)%

18.74

16.97

14.23

15.58

14.26

15.12

13.37

11.49

14.37

12.31

15.10

13.37

14.31

21

23.46

FCF margin%

35.00

32.40

31.55

32.01

31.53

31.40

33.03

34.87

37.34

35.45

27.50

34.87

32.72

78

1.406

FCF / Net incomex

1.187

1.182

1.307

1.153

1.121

1.150

1.112

1.038

0.985

0.872

0.180

1.038

1.135

92

26.30

ROIC%

27.09

27.44

29.49

28.66

31.62

32.45

33.04

31.33

29.01

31.33

27.97

31.33

30.41

27

5.70

Return on equity%

30.63

32.77

34.85

37.42

38.35

36.25

33.52

31.93

31.07

32.92

14.07

32.92

33.22

72

29.90

Return on assets%

15.49

16.32

13.33

15.45

14.21

11.42

8.73

6.67

9.53

10.09

8.57

9.53

12.38

38

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

11.89%

10.37%

—

2.48

EPS growth%

29.20

31.36

30.90

28.79

30.42

31.93

30.15

32.53

34.08

34.60

24.90

32.53

31.13

80

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

(1.56%)

0.39%

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

(5.36%)

(5.18%)

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

10.31%

10.07%

—

27.64

Div yield (avg)%

18.80

20.98

18.09

20.52

18.51

19.39

19.47

16.73

14.97

15.67

26.47

16.73

18.65

63

8.20

Payout ratio%

25.79

24.25

21.75

19.57

20.85

22.16

20.99

23.16

20.65

18.46

17.39

20.99

21.37

44

4.464

Shares (diluted)B

4.996

5.202

4.861

5.144

4.983

4.804

4.366

4.746

4.640

4.872

4.392

(0.45%)

(0.05%)

75

2.60

Buyback yield%

0.40

0.40

1.85

2.36

4.69

7.42

4.84

4.83

3.50

6.21

11.21

4.84

4.10

38

1.220

D/E ratiox

0.520

0.564

0.604

0.651

0.689

0.737

0.749

0.827

0.881

0.850

0.298

0.827

0.713

43

1.165

Enterprise value$M

3.547

4.096

3.930

4.183

4.389

4.555

4.494

5.019

4.822

4.718

2.327

1.45%

4.06%

38

2.022

LT debt$M

3.061

3.556

3.682

4.176

4.289

4.213

4.029

4.011

3.894

4.274

2.775

(0.07%)

4.44%

46

Peers (US$11.92M)

Cap (US$)

PE

Miro Sciences Ltd

12.58M

—

Algorae Pharmaceutical…

12.53M

—

Imugene Limited

12.11M

—

Xintela AB (publ)

11.93M

—

Capital

TTM

5Y

10Y

Leveragex

14.80

(0.204)

(0.175)

EBIT/Intx

0.265

0.208

0.171

Own earn%

(4.90)

(73.21)

(44.81)

Sh yield%

30.24

21.88

21.71

Owners

Insiders/Inst%

7.90

83.12

Short interest%

3.22

SBC / revenue%

3.41

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

22

Op margin range%

19–29

$1 testx

0.0

Incr. ROIC%

11

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$2.113M

4.27%

1.00×

Cost of revenue

$1.161M

4.36%

1.01×

Operating expenses

$0.399M

4.44%

1.02×